Login to Your Account

High Court to Hear Amgen's 'Fraud-on-the-Market' Case

By Mari Serebrov
Washington Editor

Tuesday, June 12, 2012
The biotech industry is hoping the Supreme Court will do what Congress hasn't been able to do – give companies a fighting chance against class-action shareholder lawsuits claiming "fraud on the market."

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription